<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="133812">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359735</url>
  </required_header>
  <id_info>
    <org_study_id>802-247-09-022</org_study_id>
    <nct_id>NCT01359735</nct_id>
  </id_info>
  <brief_title>Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients</brief_title>
  <official_title>A Phase II Randomized, Open-label Study Investigating the Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthpoint</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthpoint</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares HP802-247 versus an antibiotic ointment for healing the wound after Mohs
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator Global Assessment of Healing</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Non-melanoma Skin Cancer</condition>
  <arm_group>
    <arm_group_label>HP802-247</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>allogeneic, growth arrested keratinocytes and fibroblasts: final concentration of 5.0 M cells/mL with a ratio of 1:9 keratinocytes:fibroblasts, applied weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacitracin Ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bacitracin antibiotic ointment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HP802-247</intervention_name>
    <description>High dose HP 802-247, applied at each visit (Week 1-13) or until healed</description>
    <arm_group_label>HP802-247</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bacitracin Ointment</intervention_name>
    <description>One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).</description>
    <arm_group_label>Bacitracin Ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide informed consent.

          -  Age â‰¥ 18 years and of either sex.

          -  Type I, II, or III skin as assessed by the Fitzpatrick Scale.

          -  Willing to comply with protocol instructions, including allowing all study
             assessments.

          -  Scheduled to have head or neck non-melanoma skin cancers removed by Mohs micrographic
             surgery with final wound size of 8 mm to 20 mm in diameter or with 8 mm to 20 mm long
             axis if not circular.

          -  Acceptable state of health and nutrition, in the opinion of the Investigator.

        Exclusion Criteria:

          -  History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin,
             bovine serum albumin or bovine serum proteins, penicillin, streptomycin, or
             amphotericin B.

          -  Therapy with blood-thinning agents including aspirin within 14 days of the Baseline
             Visit (these may be resumed post-surgery).

          -  Subjects with platelet or coagulation disorders.

          -  Therapy with another investigational agent within thirty (30) days of Screening, or
             during the study.

          -  Current systemic therapy with cytotoxic drugs.

          -  Current therapy with chronic (&gt; 10 days) oral corticosteroids.

          -  In the opinion of the Investigator the subject has a current life expectancy of less
             than 1 year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert B Slade, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Healthpoint</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Derm Research PLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 19, 2013</lastchanged_date>
  <firstreceived_date>May 23, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>September 12, 2013</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wound</keyword>
  <keyword>non-melanoma skin cancer</keyword>
  <keyword>Mohs micrographic surgery</keyword>
  <keyword>Head or neck</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Bacitracin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
